Testosterone enanthate auto-injection - Antares Pharma

Drug Profile

Testosterone enanthate auto-injection - Antares Pharma

Alternative Names: QuickShot testosterone; Testosterone enantate - Antares Pharma; TRT - Antares Pharma; Vibex QS T; Vibex QuickShot T

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Antares Pharma
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypogonadism

Most Recent Events

  • 03 Apr 2017 Interim efficacy, pharmacodynamics events data from a phase III STEADY trial in Hypogonadism released by Antares Pharma
  • 27 Feb 2017 FDA assigns Prescription Drug User Fee Act date of 20-10-2017 for Hypogonadism (SC)
  • 27 Feb 2017 The US FDA accepts NDA for testosterone enanthate auto-injection for Hypogonadism for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top